Coherus BioSciences

Coherus BioSciences

Develops and commercializes biosimilars for healthcare

About Coherus BioSciences

Simplify's Rating
Why Coherus BioSciences is rated
B
Rated B on Competitive Edge
Rated A on Growth Potential
Rated C on Rating Differentiation

Industries

Biotechnology

Healthcare

Company Size

201-500

Company Stage

IPO

Total Funding

$114.5M

Headquarters

Redwood City, California

Founded

2010

Overview

Coherus BioSciences develops and sells biosimilars, which are highly similar versions of approved biologic medicines used to treat various diseases. These biosimilars are designed to be as effective and safe as the original products but are offered at a lower cost, making them more affordable for patients and healthcare systems. The company focuses on research, development, and commercialization of these products, ensuring they meet strict regulatory standards for quality and efficacy. Coherus aims to improve patient lives by expanding access to essential biologic treatments, thereby addressing the rising costs of healthcare. Their business model allows them to generate revenue through the sale of these cost-effective alternatives, giving them a competitive advantage in the biopharmaceutical market.

Simplify Jobs

Simplify's Take

What believers are saying

  • Global biosimilars market projected to grow at 24.7% CAGR from 2023 to 2030.
  • FDA guidance on biosimilar interchangeability could boost market acceptance for Coherus.
  • Collaborations with research institutes enhance development of novel therapies.

What critics are saying

  • Sandoz acquisition of Coherus' assets may lead to market share erosion.
  • 30% staff reduction could impact operational efficiency and product development.
  • Divestment of Canadian rights to Toripalimab limits revenue potential in Canada.

What makes Coherus BioSciences unique

  • Coherus focuses on cost-effective biosimilars for oncology and inflammatory diseases.
  • The company leverages advanced process science and analytical characterization in development.
  • Coherus' Udenyca wearable injector offers innovative drug delivery for pegfilgrastim.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$114.5M

Above

Industry Average

Funded Over

7 Rounds

Post IPO Equity funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Equity Funding Comparison
Coming Soon

Benefits

Competitive base salary

Target bonus based on performance

stock options

Medical, dental, & vision coverage

PTO

401(k) plan

FSA

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-2%
PE Hub
Jul 3rd, 2024
SK Capital's Apotex to acquire Canadian rights to Toripalimab

SK Capital Partners portfolio company Apotex has agreed to acquire the license to the Canadian rights to Toripalimab, an anti-PD-1 monoclonal antibody, from Coherus Biosciences.

TipRanks
Jun 5th, 2024
Coherus Biosciences Appoints Rita Karachun to Board

Coherus Biosciences appoints Rita karachun to board.

GlobeNewswire
Jun 5th, 2024
Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

Coherus BioSciences appoints Rita Karachun, CPA, CGMA to its Board of Directors.

Yahoo Finance
May 8th, 2024
Coherus Announces Clinical Collaboration With The Cancer Research Institute For A Novel Combination Evaluating Loqtorzi(R) (Toripalimab-Tpzi) With Enb Therapeutics' Enb-003 For The Treatment Of Ovarian Cancer

Coherus BioSciences, Inc.REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus; Nasdaq: CHRS) today announced that the Cancer Research Institute (CRI) and its Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC) Drug Selection Committee (DSC) have selected LOQTORZI (toripalimab-tpzi), anti-PD-1 antibody, to explore in combination with ENB-003, a first-in-class small molecule inhibitor of endothelin B receptor (ETBR), for the treatment of drug-resistant cancers in the iPROC platform study. Endothelin B receptor is implicated in tumorigenesis and tumor immune suppression for several solid tumors, including melanoma, ovarian, and pancreatic cancers.“The iPROC DSC is pleased to have access to this next-generation PD-1 inhibitor and advance this combination supported by preclinical and clinical data in this study in ovarian cancer,” said John Stagg, Ph.D., Professor, Faculty of Pharmacy at the University of Montreal and Principal Investigator, Centre Hospitalier de l’Université de Montréal (CHUM) and its affiliated Cancer Institute of Montreal.Dr. Stagg continued, “The iPROC study DSC brings together a group of scientific experts within the CRI community to select promising combinations and rapidly advance them to clinical trials. Importantly, the DSC is not confined by a pipeline but looks to work with companies with drugs that have a strong data package. For this multiparty platform study to succeed, it requires science-driven, highly collaborative, and engaged companies

Fierce Pharma
Mar 13th, 2024
Coherus again axes staff, with 30% of roles on chopping block amid 'sharpened focus' on cancer drugs

After a first-in-class FDA approval in nasopharyngeal carcinoma in October, Coherus launched Loqtorzi at the beginning of 2024.

Recently Posted Jobs

Sign up to get curated job recommendations

Coherus BioSciences is Hiring for 0 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Coherus BioSciences's jobs every 8 hours, so check again soon! Browse all jobs →